Current Report Filing (8-k)
April 08 2019 - 04:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): April 8, 2019
CANCER
GENETICS, INC.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
|
|
001-35817
|
|
04-3462475
|
(State
or Other
Jurisdiction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
201
Route 17 North 2
nd
Floor, Rutherford, New Jersey
|
|
07070
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code
(201) 528-9200
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined by Rule 405 of the Securities Act of 1933 (17 §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.08. Shareholder Director Nominations.
On
April 8, 2019, the Board of Directors of Cancer Genetics, Inc. (the “Company”) determined that the Company’s
annual meeting of stockholders (the “Annual Meeting”) will be held on May 31, 2019, at 9:00 a.m. at the Company’s
offices in Rutherford, New Jersey or at such other time and location to be determined by the authorized officers and set forth
in the Company’s proxy statement for the Annual Meeting, and established April 15, 2019 as the record date for determining
stockholders entitled to notice of, and vote at, the Annual Meeting. The Company did not hold an annual meeting in 2018. As a
result, stockholders of the Company who wish to have a proposal considered for inclusion in the Company’s proxy materials
for the Annual Meeting pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)
must provide written notice to the Company at its corporate headquarters, 201 Route 17 North, 2nd Floor, Rutherford, New Jersey
07070, on or before April 18, 2019, which the Company has determined to be a reasonable time before it expects to begin to print
and mail its proxy materials. Stockholder proposals intended to be considered for inclusion in the Company’s proxy materials
for the Annual Meeting must comply with the deadline set forth above as well as all the applicable rules and regulations promulgated
by the Securities and Exchange Commission under the Exchange Act. In addition, pursuant to the Company’s bylaws, stockholders
who wish to nominate a person for election as a director or submit a proposal for inclusion at the Annual Meeting must provide
written notice to the Company at its corporate headquarters on or before April 18, 2019. Any such written notice must be directed
to the attention of the Company’s Secretary at the Company’s corporate headquarters and must comply with the applicable
provisions of the Company’s bylaws, as amended.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CANCER GENETICS, INC.
|
|
|
|
|
By:
|
/s/
John A. Roberts
|
|
Name:
|
John
A. Roberts
|
|
Title:
|
Chief
Executive Officer
|
|
|
|
Date:
April 8, 2019
|
|
|
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Mar 2023 to Mar 2024